Adar Poonawalla is the CEO of Serum Institute of India.

Poonawallla joined his father’s company Serum Institute of India in 2001 and became CEO in 2011. Then exporting its products to 35 countries, Poonawalla concentrated on the company’s international market and on getting new products licensed and pre-qualified by the World Health Organization, for supply to United Nations Agencies including UNICEF and PAHO. As of 2015, the company now exports its products to over 140 countries worldwide, out of which 85 percent of its revenues are from overseas.

In 2011, he became the CEO of Serum Institute with complete control of the day-to-day operations of the company. In 2012, he played a major role in the acquisition of Bilthoven Biologicals, a Netherlands-based government vaccine manufacturing company. Poonawalla is also associated as a board member of the GAVI Alliance, which is the global Vaccine Alliance.

He initiated and launched Serum Institute’s Oral Polio Vaccine in 2014, which addressed a global shortage of Polio vaccines at that time, and every year plans to launch a new vaccine for public health starting in 2017. In 2014, it was reported that he also planned to expand the product portfolio to include vaccines for dengue, flu, and cervical cancer.

He is the recipient of many business and philanthropy awards from CNBC TV18, CNN TV18, Economic Times, Hurun, and many others, to name a few in the recent past.

In 2013, he hosted His Royal Highness, Prince Charles of Wales, and The Duchess of Cornwall, during a private visit to Serum Institute’s manufacturing facility in India.

He was also listed as one of the 50 most influential young Indians by the GQ Magazine and also was awarded Philanthropist of the year in 2016.

In 2011, he founded the Villoo Poonawalla Foundation, in memory of his late mother Mrs. Villoo Poonawalla. The main objective of the Foundation is to enhance lives through a primary focus on education, health care, water, and environmental sanitation, and green spaces.

Vaccines, Fortune, Business, COVID-19